A Study to Evaluate Efficacy and Safety of AL001 in FTD (INFRONT-3)

A Phase 3 clinical study investigating the efficacy of AL001 in slowing the progression of FTD in progranulin gene mutation carriers


Alector, Inc. is studying AL001 as a new experimental drug for frontotemporal dementia (FTD) caused by mutations in the progranulin gene. These mutations reduce progranulin levels in the body and may lead to symptoms of FTD.

The purpose of the INFRONT-3 study is to determine if increasing progranulin levels with treatment of the experimental drug will delay onset of symptoms or slow disease progression, when compared to a placebo (a solution that contains no active AL001 drug). Participants need to have a confirmed progranulin gene mutation, and either diagnosed with FTD or at risk of developing FTD symptoms as evidenced by a biomarker. The study drug (AL001 or placebo) will be administered every 4 weeks by an intravenous (IV) infusion. Assessments will include regular medical examinations, blood tests, brain imaging, and completion of questionnaires.

Please contact Neurology Research Partners at 303-724-4644 or  NeurologyResearchPartners@cuanschutz.edu to learn more and see if you qualify.

You can also find more information about the study and the research sites participating in the study by calling 1-833-FindFTD (1-833-346-3383) or visiting  https://clinicaltrials.gov/ct2/show/NCT04374136


AL001has not been approved by the FDA or any other health authority approval around the world.


Navy blue and yellow logo for Alector, Inc.


CMS Login